July 9 (Reuters) – Bausch + Lomb said on Thursday its glaucoma eye drop had missed the main goal in a mid-stage trial of replicating visual function improvements observed in a smaller study.
The company said it will discontinue development of the eye drops for glaucoma-related vision improvement.
Here are further details: –
• Bausch acquired the eye drop BL1107 through a buyout of Whitecap Biosciences last year.
• U.S.-listed shares of the company were down 2.8% in extended trading.
• The company said it will continue pursuing a sustained-release implant for the treatment of vision-threatening diseases, with a primary focus on geographic atrophy, an advanced, late stage of dry age-related macular degeneration.
• Bausch expects clinical trials of the implant to begin in 2028.
• “We’ve intentionally built a diversified pipeline … not every program will succeed, but every study helps us make smarter decisions about where to invest,” said Bausch’s medical chief Yehia Hashad.
(Reporting by Puyaan Singh in Bengaluru; Editing by Tasim Zahid)
